Publication date: 03/07/2018
Biogazelle is pleased to announce the appointment of Armin Winands as its new CEO effective 1st July 2018, following Jan Hellemans who will take on the role of CTO after 10 years as CEO.
From qPCR to molecular test development
The appointment of Winands is part of Biogazelle’s strategy to position itself as a respected European player in the field of molecular test discovery, development and analysis. With its internationally recognized expertise in gene expression and liquid biopsies, Biogazelle is convinced that its unique service offering is a valuable contribution to the field of precision medicine.
Since first offering qPCR services to its clients in 2011, Biogazelle’s ambition has always been to deliver outstanding quality and technically valid results. More recently, Biogazelle has broadened its activities towards molecular test development, further building on years of experience in quantitative PCR and RNA sequencing of clinical samples.
With its innovative service, Biogazelle targets pharmaceutical companies, central labs and contract research organizations aiming at incorporating biomarker analyses in various therapeutic areas.
Leveraging talent to excel
Winands looks forward to leading the company through its next phase of innovation and spur rapid growth.
“I am incredibly proud and excited to lead Biogazelle and execute our global strategy following our vision of becoming a highly valued partner to our customers developing diagnostics and therapeutics. Biogazelle has a fantastic business and with its expertise in biomarker discovery, clinical assay development and liquid biopsies we are set up very well to serve our customers. The deep pool of talent, motivation and customer focus differentiates our team and makes us the preferred partner for our customers.”
— Armin Winands, PhD, newly appointed CEO of Biogazelle —
Winands is a highly experienced, successful and well-regarded business leader. He has gained experience in the markets of genetic testing, biomarker discovery and clinical assay development since 2010 and has built expertise in building and leading international teams for over 20 years. Winands is a people- and customer-focused individual with strong history of managing highly engaged and results oriented teams.
Simultaneous to the appointment of Winands, Biogazelle has expanded its pool of talent with two experienced sales managers in Europe and two skilled project managers responsible for providing value to the customers.
“In the last few years, we have been working hard to establish state-of-the art solutions in a professional organization with all applicable quality assurance measures in place.
Going forward, I am eager to work with Armin as CEO. His demonstrated talents to lead commercial teams will be essential for the continued growth of Biogazelle in an
— Jan Hellemans, CTO and co-founder of Biogazelle —
Exploiting RNA to improve healthcare
Biogazelle, specialized in liquid biopsies and (non-coding) RNA, supports scientist in the development of diagnostics and therapeutics by offering innovative solutions in a quality environment. Biogazelle offers expert genomic and transcriptomic services performed in an ISO17025 accredited and GCLP-compliant laboratory to support research, clinical trials and precision medicine.